Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.61 |
| ▸ | CES1 | P23141 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 4/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 5/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | CASP1 | P29466 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | PARP1 | P09874 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | ELANE | P08246 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9863135 | 0.88 | ALDH1A1 (0.56) | CES2CES1SMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL1339641 | 0.85 | CES2 (0.51) | CES2CES1LMNASMN1; SMN2POLB | |
| SCHEMBL29697823 | 0.85 | CES2 (0.51) | CES2CES1LMNASMN1; SMN2POLB | |
| SCHEMBL1339638 | 0.85 | CES2 (0.51) | CES2CES1LMNASMN1; SMN2POLB | |
| SCHEMBL884596 | 0.84 | CES2 (0.50) | CES2CES1LMNASMN1; SMN2POLB | |
| SCHEMBL27397739 | 0.84 | LMNA (0.55) | CES2CES1LMNASMN1; SMN2POLB | |
| SCHEMBL2007367 | 0.83 | TDP1 (0.53) | SMN1; SMN2TDP1MAPTALDH1A1NPSR1 | |
| SCHEMBL641903 | 0.83 | POLB (0.62) | CES2CES1LMNASMN1; SMN2POLB | |
| SCHEMBL31237097 | 0.83 | POLB (0.62) | CES2CES1LMNASMN1; SMN2POLB | |
| SCHEMBL2529911 | 0.82 | CES2 (0.56) | CES2CES1LMNASMN1; SMN2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111170991-B | Antiproliferative compounds and methods of synthesis thereof | 细胞基因公司 | 2023-10-31 | — | — | CN | disclosed |
| EP-3594211-B1 | ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF | CELGENE CORP (US) | 2023-10-25 | — | — | EP | disclosed |
| US-20220387413-A1 | ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF | CELGENE CORP (US) | 2022-12-08 | — | — | US | disclosed |
| US-11241423-B2 | Antiproliferative compounds and methods of use thereof | CELGENE CORPORATION (US) | 2022-02-08 | — | — | US | disclosed |
| US-20200163948-A1 | ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF | CELGENE CORP (US) | 2020-05-28 | — | — | US | disclosed |
| CN-111170991-A | Antiproliferative compounds and methods of synthesis thereof | 细胞基因公司 | 2020-05-19 | — | — | CN | disclosed |
| CN-106660991-B | Antiproliferative compounds and methods of use thereof | 细胞基因公司 | 2020-03-13 | — | — | CN | disclosed |
| EP-3166937-B1 | ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF | CELGENE CORP (US) | 2019-09-04 | — | — | EP | disclosed |
| US-20180221361-A1 | ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF | CELGENE CORP (US) | 2018-08-09 | — | — | US | disclosed |
| US-9968596-B2 | Antiproliferative compounds and methods of use thereof | CELGENE CORPORATION (US) | 2018-05-15 | — | — | US | disclosed |
| WO-2016007848-A1 | ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF | CELGENE CORPORATION (US) | 2016-01-14 | — | — | WO | disclosed |
| CN-103958465-A | Phenyl derivative | ONO PHARMACEUTICAL CO | 2014-07-30 | — | — | CN | disclosed |
| CN-103702985-A | Quinoxalines and aza-quinoxalines as crth2 receptor modulators | MERCK SHARP & DOHME | 2014-04-02 | — | — | CN | disclosed |
| US-20130303517-A1 | QUINOXALINES AND AZA-QUINOXALINES AS CRTH2 RECEPTOR MODULATORS | MERCK SHARP & DOHME LLC | 2013-11-14 | — | — | US | disclosed |
| US-20130303517-A1 | QUINOXALINES AND AZA-QUINOXALINES AS CRTH2 RECEPTOR MODULATORS | MERCK SHARP & DOHME LLC | 2013-11-14 | — | — | US | disclosed |
| US-20130303517-A1 | QUINOXALINES AND AZA-QUINOXALINES AS CRTH2 RECEPTOR MODULATORS | MERCK SHARP & DOHME LLC | 2013-11-14 | — | — | US | disclosed |
| EP-2661428-A1 | QUINOXALINES AND AZA-QUINOXALINES AS CRTH2 RECEPTOR MODULATORS | Merck Sharp & Dohme Corp. (US) | 2013-11-13 | — | — | EP | disclosed |
| WO-2012087861-A1 | QUINOXALINES AND AZA-QUINOXALINES AS CRTH2 RECEPTOR MODULATORS | MERCK SHARP & DOHME CORP. (US) | 2012-06-28 | — | — | WO | disclosed |
| CN-101448824-A | 2,5-disubstituted piperidines | SPEEDEL EXPERIMENTA AG (CH) | 2009-06-03 | — | — | CN | disclosed |
| EP-0386940-A1 | 6-Beta-(alpha-etherified oxymino)-acyl amino penicillins | BEECHAM GROUP PLC (GB) | 1990-09-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130303517-A1 | QUINOXALINES AND AZA-QUINOXALINES AS CRTH2 RECEPTOR MODULATORS | HRH2, NPY2R, CNKSR1 | CES2 3679/4885CES1 2561/4885LMNA 3865/4885 |
| US-20220387413-A1 | ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF | MCL1, MKI67, BAX | CES2 1769/4885CES1 2941/4885LMNA 998/4885 |
| US-11241423-B2 | Antiproliferative compounds and methods of use thereof | MCL1, MKI67, BAX | CES2 1769/4885CES1 2941/4885LMNA 998/4885 |
| US-20200163948-A1 | ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF | MCL1, MKI67, BAX | CES2 1769/4885CES1 2941/4885LMNA 998/4885 |
| US-20180221361-A1 | ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF | MCL1, MKI67, BAX | CES2 1769/4885CES1 2941/4885LMNA 998/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.